BUSINESS
Indian pharma market grew 8.7% in August on slower offtake of anti-infectives
IPM grew close to 10 percent in first five months of this financial year FY19, returning to the 10 percent growth of FY17.
BUSINESS
Tata Power plans big play in nascent rooftop solar power generation market
Tata Power management considers renewables as one of the key growth focus areas and is targeting 40-50 percent of its total generation capacity from non-fossil fuel based generation sources by 2025.
BUSINESS
Actavis to Sandoz, Aurobindo Pharma is scaling up biz one acquisition at a time
Aurobindo’s past record of integrating and turning around acquired companies is what keeps investors excited about.
BUSINESS
Abbott gets reprieve from Supreme Court in FDC ban case
The court directed the Central government to exclude 15 fixed dose combination (FDC) medications from the ban recommended by a sub-committee appointed by Drugs Technical Advisory Board.
BUSINESS
Pharma weekly wrap: A busy week with Aurobindo's US buyout and break-up of Singh brothers
The cheaper valuation of the acquisition target and Aurobindo's past track record in integrating and turning around acquired companies made most analysts and investors give was thumbs-up to the deal
BUSINESS
IRCON International to monetise its BOT road assets
IRCON has four road assets in Maharashtra, Rajasthan, Madhra Pradesh and Karnataka that are valued around Rs 4700 crore.
BUSINESS
Fortis chairman says focusing on strengthening governance, transparency
Fortis shareholders last month approved the sale of their company to Malaysia’s IHH Healthcare in $1.1 billion deal. The deal is awaiting approval from Competition Commission of India (CCI) to be consummated.
BUSINESS
Fortis saga: NCLT admits Shivinder's petition alleging financial misconduct, forgery against Malvinder
In the 43-page petition, Shivinder alleged his brother Malvinder and Godhwani for perpetrating “oppression and mismanagement” and sought removal of Malvinder from the board of RHC and restitution of funds diverted by the duo.
BUSINESS
Aurobindo Pharma acquires Sandoz's dermatology & oral solid biz in US for $900 million
The deal will position Aurobindo as the second-largest dermatology player and the second-largest generics company in the US by prescriptions.
BUSINESS
Is it too late for Shivinder Singh to absolve himself from the group’s troubles?
Shivinder Singh, the younger sibling, broke his silence on Tuesday accusing his brother Malvinder and family friend Sunil Godhwani for systemically undermining the interests of the group companies and their shareholders
BUSINESS
Competition Commission to investigate unfair pricing by private hospitals in Delhi
The Commission noted that huge profit margins are being earned by sale of products to the locked-in in-patients to the detriment of such patients.
BUSINESS
J&J faulty hip implant case: Govt appoints 5-member central expert committee to determine compensation for patients
The five-member Central expert committee will review the reports of state level committees or applications submitted by affected patients based parameters such as degree of disability and patient suffering on account of monetary loss due to loss of wages and other losses. The base amount was fixed at Rs 20 lakh.
BUSINESS
India to unveil Charter of Patients' Rights soon
The charter, prepared by the National Human Rights Commission, lays down 17 basic rights of citizens
BUSINESS
E-pharmacies welcome govt draft rules, say compliance shouldn't be a problem
The draft notes e-pharmacies will have to pay Rs 50,000 to renew licenses and the premises from where e-pharmacies operate will be inspected every two years.
BUSINESS
J&J's faulty hip implant: Expert panel says gaps in follow-up care and compensation to patients
A 11-member expert committee was constituted in February 2017 under Dr Arun Agarwal to examine issues related to faulty ASR hip implants based on complaints made by some patients.
BUSINESS
J&J's faulty hip implant: Group of patients seeks expedited release of expert panel report
The patient group has written to health minister JP Nadda alleging that officials in the CDSCO and in the Ministry of Health and Family Welfare were sitting on the expert committee report without providing any reasons for not making it public.
BUSINESS
Indian drug makers see hike in Chinese raw material as an opportunity to produce locally
There are around 7,000 active pharmaceutical ingredient manufacturers in China, catering to around 80 percent of India drug makers’ raw material needs.
BUSINESS
Pharma weekly wrap: Singh bros put blame on former top executive Sunil Godhwani for group's financial woes
Godhwani was leading group's financial services arm Religare Enterprises as MD and CEO, was also in charge of the group's holding company, RHC Holding.
BUSINESS
WHO classifies bedaquiline as priority drug in multi-drug resistant TB treatment
WHO, however, warned that it does not have evidence on the safety and effectiveness of bedaquiline use beyond six months, as it was insufficient for review
BUSINESS
Government to launch Ayushman Bharat with public hospitals only, initially
Insurance companies are hoping to play a larger role in the health insurance scheme from 2019 onwards. Due to the proposed low rates, private hospitals have been reluctant to join
BUSINESS
Ayushman Bharat: States still in wait-and-watch mode
Sources told Moneycontrol that there could be a grand launch in states like Gujarat and Haryana tomorrow.
BUSINESS
Fortis Health posts Rs 52.8 crore Q1 loss; shareholders approve $1.1 bn deal with IHH
The deal now needs a go ahead from Competition Commission of India (CCI) to be consummated.
BUSINESS
No reason for pvt hospitals to sit out of path-breaking govt initiative: Ayushman Bharat CEO
“We want to make sure that rates are high enough so that we can attract the private sector, but at the same time they should not be so high that they make the scheme unsustainable,” Bhushan said.
BUSINESS
California verdict on Monsanto's Roundup could have India implications
The latest annual report of Monsanto’s India unit states that its brand Roundup maintains market leadership with sales of around Rs 185.66 crore, which is 28 percent of its net sales of Rs 667.44 crore in FY18
